Sensus Healthcare Receives FDA 510k Clearance for Next Generation Image Guided Superficial Radiotherapy SRT-100 Vision(TM)
October 19, 2015
San Antonio, TX
(GLOBE NEWSWIRE) Sensus Healthcare, the market leader in superficial radiation therapy treatment of skin cancer and keloids, announces FDA clearance for the next generation SRT-100 Vision™ system at the American Society for Radiation Oncology (ASTRO) 2015 exhibition in San Antonio, TX. The next generation SRT-100 Vision™ features unique integration of multi-modal therapy and image-guidance technologies with software integration to provide enhanced precision, safety, and quality in delivering superficial radiotherapy (SRT), electronic brachytherapy (eBx), and Grenz Ray therapy (GRT) in a seamlessly integrated and scalable platform.
“Sensus continues to focus on patient outcomes by providing physicians who treat NMSC and keloids with the tools to optimize their treatment options.” stated Joe Sardano, President and CEO of Sensus Healthcare.
According to Sensus’ Chief Technology Officer, Mr. Kal Fishman: “Our systems around the world have treated more patients, more skin cancers, and keloids than any other device. We are dedicated to providing all the tools necessary to achieve maximum results.”
The SRT-100 Vision™ is also FDA-cleared for the treatment of keloids following surgical removal, allowing prophylactic treatment for this chronic condition to general surgery patients who are predisposed to their development.
Come and visit us at booth 885 to learn more and experience the next generation SRT-100 Vision™ system.
About Sensus Healthcare
Sensus Healthcare LLC (Boca Raton, FL) is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy x-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visithttps://www.sensushealthcare.com.
The American Society for Radiation Oncology (www.astro.com) is the premier radiation oncology society in the world, with nearly 11,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals that specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, the Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy.
LHA Investor Relations
The Benefits of SRT
Along with eliminating the risks for post-surgical infections and complications, the SRT-100™ provides patients and physicians with a safe and effective treatment option that offers many benefits, including:
- 95%+ cure rates that rival surgery
- No anesthesia, cutting, bleeding, stitching or pain
- No downtime or lifestyle restrictions
- Super cosmesis, no unsightly scarring
- No need for post-treatment reconstructive surgeries